Prospective Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Orthop. Mar 18, 2024; 15(3): 257-265
Published online Mar 18, 2024. doi: 10.5312/wjo.v15.i3.257
Mid-term survival of the Optimys short stem: A prospective case series of 500 patients
Bryan Hamans, Sheryl de Waard, Sjoerd Kaarsemaker, Esther R C Janssen, Inger N Sierevelt, Gino M M J Kerkhoffs, Daniël Haverkamp
Bryan Hamans, Department of Orthopaedic Surgery, Xpert Clinic, Amsterdam 1101EA, Netherlands
Sheryl de Waard, Department of Orthopedic Surgery, Amsterdam University Medical Center, Amsterdam 1105 AZ, Netherlands
Sjoerd Kaarsemaker, Esther R C Janssen, Department of Orthopaedic Surgery, Viecuri Medisch Centrum, Venlo 5912 BL, Netherlands
Inger N Sierevelt, Centre for Orthopaedic Research, Spaarne Ziekenhuis, Hoofddorp 2134 TM, Netherlands
Gino M M J Kerkhoffs, Department of Orthopaedic Surgery and Sports Medicine, Amsterdam UMC-Location AMC, Amsterdam 1105 AZ, Netherlands
Daniël Haverkamp, Department of Orthopedic Surgery, Xpert Orthopedic Surgery Clinic, Amsterdam 1101 EA, Netherlands
Author contributions: Hamans B and Sierevelt IN analyzed the data; Hamans B, de Waard S, Kaarsemaker S, Janssen ERC, Sierevelt IN, Kerkhoffs GMMJ, and Haverkamp D prepared the manuscript; de Waard S, Kaarsemaker S, and Haverkamp D included patients; de Waard S, Kaarsemaker S, Janssen ERC, Sierevelt IN, and Haverkamp D collected data; Sierevelt IN and Haverkamp D designed the research study; All authors read and approved the final manuscript.
Institutional review board statement: This study was reviewed and approved by the Slotervaarziekenhuis en Reade Institutional Review Board (approval No. NL47055.048.13).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: There are no conflicts of interest for any of the authors regarding this study.
Data sharing statement: Dataset is available from the corresponding author at s.dewaard21@gmail.com. Participants gave informed consent for using their data for publication.
CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Sheryl de Waard, MD, Department of Orthopedic Surgery, Amsterdam University Medical Center, Meibergdreef 9, Amsterdam 1105 AZ, Netherlands. s.dewaard21@gmail.com
Received: November 1, 2023
Peer-review started: November 1, 2023
First decision: November 29, 2023
Revised: December 13, 2023
Accepted: January 16, 2024
Article in press: January 16, 2024
Published online: March 18, 2024
Processing time: 134 Days and 12 Hours
Core Tip

Core Tip: The Optimys hip stem showed an excellent 5-year survival of 98.9%, and when excluding infections this was 99.4%. This is in line with the earlier results of the Roentgen Stereophotogrammetric analysis study completed by our group, and we expect it to be in line with the National Institute for Health and Care Excellence criteria on total hip arthroplasty for the 10-year follow-up. This study showed that in a large, varied patient population there is similar survival as other cohorts with short femoral stems.